Your browser doesn't support javascript.
loading
Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada.
Langer, Anatoly; Tan, Mary; Goodman, Shaun G; Grégoire, Jean; Lin, Peter J; Mancini, G B John; Stone, James A; Leiter, Lawrence A.
Afiliação
  • Langer A; Canadian Heart Research Centre, North York, ON, Canada.
  • Tan M; Canadian Heart Research Centre, North York, ON, Canada.
  • Goodman SG; Canadian Heart Research Centre, North York, ON, Canada.
  • Grégoire J; St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Lin PJ; Institut de cardiologie de Montréal, Université de Montréal, Montréal, QC, Canada.
  • Mancini GBJ; Canadian Heart Research Centre, North York, ON, Canada.
  • Stone JA; University of British Columbia, Vancover, BC, Canada.
  • Leiter LA; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Int J Clin Pract ; 75(4): e13861, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33244861
ABSTRACT

BACKGROUND:

We studied whether significant differences in care gaps exist between specialists and primary care physicians (PCPs).

METHODS:

GOAL Canada enrolled patients with CVD or familial hypercholesterolemia (FH) and LDL-C > 2.0 mmol/L despite maximally tolerated statin therapy. During follow-up, physicians received online reminders of treatment recommendations based on Canadian Guidelines.

RESULTS:

A total of 177 physicians (58% PCPs) enrolled 2009 patients; approximately half of the patients were enrolled by each physician group. Patients enrolled by specialists were slightly older (mean age 63 years vs 62), female (45% vs 40%), Caucasian (77% vs 65%), and had a slightly higher systolic pressure and lower heart rate. Patients enrolled by specialists had less frequent history of FH, diabetes, hypertension, chronic kidney disease and liver disease but more frequent history of coronary artery disease, atrial fibrillation and premature family history of CVD. There was no significant baseline difference in LDL-C, HDL-C or non-HDL-C, although total cholesterol and triglycerides were slightly higher in patients managed by PCPs. At baseline, PCPs were more likely to use statins (80% vs 73%, P = .0002) and other therapies such as niacin or fibrate (10% vs 6%, P = .0006) but similar use of ezetimibe (24% vs 27%, P = .15). At the end of follow-up, specialists used less statins (70% vs 77%, P = .0005) and other therapies (6% vs 10%, P = .007) but more ezetimibe (45% vs 38%, P = .01) and the same frequency of PCSK9i (28% vs 27%, P = .65). The proportion of patients achieving the recommended LDL-C level of 2.0 mmol/L or below (primary endpoint) was similar at last available visit between specialists and PCPs (44% vs 42%, P = .32).

CONCLUSION:

Despite minor differences in the clinical profile of their patients, both PCPs and specialists actively participate in the management of lipid-lowering therapy in high-risk CVD patients and experience similar challenges and care gaps.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Anticolesterolemiantes Tipo de estudo: Guideline Limite: Female / Humans / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Anticolesterolemiantes Tipo de estudo: Guideline Limite: Female / Humans / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article